Share ownership Fortress Biotech, Inc.

FBIO

US34960Q3074

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-05 pm EST			5-day change	1st Jan Change
3.130 ^USD	+0.97%		-11.08%	-14.48%

Feb. 23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
Jan. 13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE

Share class: Fortress Biotech, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	27,604,934	21,758,792 ( 78.82 %)	0	78.82 %
Stock B	0	3,427,138	0	0

Major shareholders: Fortress Biotech, Inc.

Name	Equities	%	Valuation
Lindsay Rosenwald 13.25 %	4,111,417	13.25 %	13 M $
Michael Weiss 5.803 %	1,801,138	5.803 %	6 M $
Vanguard Fiduciary Trust Co. 3.546 %	1,100,570	3.546 %	3 M $
Opaleye Management, Inc. 3.512 %	1,090,000	3.512 %	3 M $
Summit Financial LLC 1.417 %	439,928	1.417 %	1 M $
Shikiar Asset Management, Inc. 0.8972 %	278,469	0.8972 %	863 254 $
Geode Capital Management LLC 0.8457 %	262,492	0.8457 %	813 725 $
Northern Trust Investments, Inc.(Investment Management) 0.7717 %	239,532	0.7717 %	742 549 $
Susquehanna Securities LLC 0.7403 %	229,777	0.7403 %	712 309 $
Sculptor Capital LP 0.673 %	208,900	0.673 %	647 590 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	20.29%
Institutional	17.57%
Other	1.1%
State Street Corp.	0.25%
Unknown	60.79%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	20.29%
United States	18.59%
United Kingdom	0.27%
Cayman Islands	0.05%
Canada	0.01%

Based on 1000 largest holdings

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

Employees

101

Sector

Pharmaceuticals

More about the company